■我们的疾病成本(COI)模型在5年的时间范围内采用了付款人和社会观点来衡量台湾系统性红斑狼疮(SLE)的经济负担。
■建立了基于患病率的模型,以估计台湾诊断后SLE的经济后果。该模型包括四个健康状态:(I)代表轻度的三种表型,中度,严重的SLE,(二)死亡。输入来自所有临床试验的文献综述,并使用Delphi小组进行验证。Delphi小组的见解包括台湾医疗系统中SLE患者常用的治疗策略。这个模型中提到的费用是疾病管理,监测,瞬态事件,和间接成本。进行了单向灵敏度分析以评估模型的不确定性。
■在我们的COI模型中,SLE患者人数为20,189。诊断时,轻度SLE患者的数量,中度,严重表型分别为5916、12255和2019年。从付款人和社会的角度来看,台湾5年的SLE总成本估计为3.9TWD和470亿,分别。从付款人和社会角度来看,每位患者每年的费用分别为38,775TWD(2,758美元)和466,119TWD(33,152美元),分别。
■研究结果表明,台湾SLE在5年内的负担相当高,主要是由于经济损失的后果,因为它影响到工作年龄的女性和男性,除了SLE管理的成本及其后果之外,比如耀斑,感染,和器官损伤。因此,应更加注意限制SLE的进展和耀斑的发生,和进一步的经济评估是必要的,以评估新的治疗策略,可以控制疾病。
UNASSIGNED: Our cost-of-illness (COI) model adopted both payer and societal perspectives over a time horizon of 5 years to measure the economic burden of systemic lupus erythematosus (SLE) in Taiwan.
UNASSIGNED: A prevalence-based model was established to estimate the economic consequences of SLE after diagnosis in Taiwan. The model included four health states: (i) the three phenotypes representing mild, moderate, and severe SLE, and (ii) death. The inputs were obtained from a literature review of all the clinical trials and validated using a Delphi panel. The Delphi panel\'s insights included commonly used treatment strategies for patients with SLE within the Taiwanese healthcare system. The costs mentioned in this model are disease management, monitoring, transient event, and indirect costs. One-way sensitivity analyses were conducted to assess the model uncertainty.
UNASSIGNED: The number of patients with SLE in our COI model was 20,189. At diagnosis, the number of SLE patients with mild, moderate, and severe phenotypes was 5,916, 12,255, and 2019, respectively. The total SLE cost in Taiwan over 5 years from both payer and societal perspectives was estimated at TWD 3.9 and 47 billion, respectively. The costs per patient per year from the payer and societal perspective were TWD 38,775 ($2,758) and TWD 466,119 ($33,152), respectively.
UNASSIGNED: The findings demonstrated that the burden of SLE in Taiwan over a time horizon of 5 years is substantially high, mainly due to the consequences of economic loss as it affects women and men during their working age, in addition to the costs of SLE management and its consequences, such as flares, infection, and organ damage. Therefore, more attention should be paid to limiting the progression of SLE and the occurrence of flares, and further economic evaluations are necessary to assess novel treatment strategies that could control the disease.